Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia**

Author： Hernandez Enrique   Ganly Peter   Charu Veena   DiBenedetto Joseph   Tomita Dianne   Lillie Tom   Taylor Kerry    

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.9, 2009-09, pp. : 2109-2120

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia

By Kotasek Dusan   Canon Jean-Luc   Mateos Maria Victoria   Hedenus Michael   Rossi Greg   Taylor Kerry  

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1387-1401

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial

By  

DIABETIC MEDICINE, Vol. 32, Iss. 4, 2015-04 ,pp. : 531-541

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chemotherapy-induced anemia: the story of darbepoetin alfa

By Vansteenkiste Johan   Wauters Isabelle   Elliott Steven   Glaspy John   Hedenus Michael  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 325-337

Informa Healthcare

Access to resources Recommend Favorite

Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial

By Boureau F.   Legallicier P.   Kabir-Ahmadi M.  

Pain, Vol. 104, Iss. 1, 2003-07 ,pp. : 323-331

Elsevier

Access to resources Recommend Favorite

A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease

By  

MOVEMENT DISORDERS, Vol. 28, Iss. 10, 2013-09 ,pp. : 1407-1415

John Wiley & Sons Inc

Access to resources Recommend Favorite